Sage Therapeutics Income Statement

Financials in millions ILS. Fiscal year is January - December.

Millions ILS. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	0.03	0.12	0.09	-	-
Other Revenue	3.48	0.27	0.07	0	-
Revenue	3.51	0.39	0.16	0	-
Revenue Growth (YoY)	793.13%	142.59%	5300.00%	-	-
Gross Profit	3.51	0.39	0.16	0	-
Selling, General & Admin	3.23	3.57	4.31	4.02	0.94
Operating Expenses	3.23	3.57	4.31	4.02	0.94
Operating Income	0.28	-3.18	-4.14	-4.02	-0.94
EBT Excluding Unusual Items	0.28	-3.18	-4.14	-4.02	-0.94
Gain (Loss) on Sale of Investments	-	-1.43	-1.49	-	-
Pretax Income	0.28	-4.61	-5.64	-4.02	-0.94
Net Income	0.28	-4.61	-5.64	-4.02	-0.94
Net Income to Common	0.28	-4.61	-5.64	-4.02	-0.94
Shares Outstanding (Basic)	4	4	4	4	-
Shares Outstanding (Diluted)	4	4	4	4	-
Shares Change (YoY)	-	-0.30%	21.05%	-	-
EPS (Basic)	0.07	-1.08	-1.32	-1.14	-
EPS (Diluted)	0.07	-1.08	-1.32	-1.14	-
Free Cash Flow	-1.82	-2.41	-4.03	-3.23	-
Free Cash Flow Per Share	-0.43	-0.56	-0.94	-0.92	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	7.98%	-808.14%	-2558.03%	-134033.33%	-
Profit Margin	7.98%	-1172.26%	-3479.01%	-134033.33%	-
Free Cash Flow Margin	-51.97%	-612.47%	-2488.89%	-107566.67%	-
EBITDA	0.28	-3.17	-4.14	-4.02	-
EBITDA Margin	8.09%	-	-	-	-
D&A For EBITDA	0	0.01	0.01	0	-
EBIT	0.28	-3.18	-4.14	-4.02	-0.94
EBIT Margin	7.98%	-	-	-	-
Revenue as Reported	3.51	0.39	0.16	0	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.